JaLCDOI 10.18926/AMO/56079
フルテキストURL 72_3_315.pdf
著者 Miyata, Yasuhiko| Saito M. , Akiko| Yano, Takahiro| Yoshida, Isao| Suehiro, Youko| Harada, Naoki| Nagai, Hirokazu|
抄録 In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
キーワード rituximab diffuse large B-cell lymphoma open-label single arm trial
Amo Type Clinical Study Protocol
発行日 2018-06
出版物タイトル Acta Medica Okayama
72巻
3号
出版者 Okayama University Medical School
開始ページ 315
終了ページ 318
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29926011